<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D"><gtr:id>DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D</gtr:id><gtr:name>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Wellcome Trust Centre for Human Genetics</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D"><gtr:id>DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D</gtr:id><gtr:name>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1ECAC33F-3736-406C-8812-314084A0A6CB"><gtr:id>1ECAC33F-3736-406C-8812-314084A0A6CB</gtr:id><gtr:firstName>Climent</gtr:firstName><gtr:surname>Casals-Pascual</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701885"><gtr:id>7A618298-9B4B-433A-B61A-B05D4D4DFE02</gtr:id><gtr:title>Pathobiological classification of severe malaria based on an integrated approach of high-throughput proteomics and syste</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0701885</gtr:grantReference><gtr:abstractText>Severe malaria (SM) is caused by the parasite Plasmodium falciparum. It is an important cause of death mainly in children under five years of age. The current definition of SM includes various severe syndromes with associated mortalities ranging from 4% to 35% despite adequate treatment. 

Proteins are involved in almost any biological function. The comprehensive study of all the proteins (the proteome) provides a global perspective of how a biological system works. Therefore, emerging technologies like proteomics offer powerful new tools to disentangle the mechanisms of complex diseases and help identify new therapeutic targets.

The plasma proteome includes all the proteins that can be found in the fluid phase of the blood. In this study we aim to identify the plasma proteome of children with SM, which will help us identify key molecules that participate in the development of severe disease. The identification of these molecules or biomarkers will provide a better understanding of the underlying mechanisms of SM, which may be translated into better diagnosis, management and eventually decrease the mortality of severe malaria.</gtr:abstractText><gtr:technicalSummary>Aim: The overall aim of this research proposal is to study the molecules involved in the pathophysiology of severe malaria to improve its diagnosis and clinical management.
Objectives: 1-To identify and quantitate the peptides and proteins that constitute the plasma proteome of children with Plasmodium falciparum severe malaria (CM, SRD, SMA and other severe infections) and mild malaria and healthy controls; 2- to assess the diagnostic performance of distinctive peptide/proteins identified; and 3-to integrate these data into predictive models that may explain differences in clinical outcome in severe malaria.
Design: I will use shotgun proteomics to describe the plasma proteome in each of the severe malaria groups (n= 200 per group) and controls (n=100) and a systems biology approach to integrate three levels of biological information (proteomics, clinical and genome-wide data) into predictive models that may explain differences in clinical outcome in severe malaria and may provide a better framework for risk stratification. 

Methods: This study will analyse plasma samples that have been collected in The Gambia from 1997 to 2006. 
1- Data acquisition: a combination of off-gel electrophoresis, high performance liquid chromatography and tandem mass spectrometry (LC-MS/MS) will be performed to study the plasma proteome of patients and controls; the acquired MS/MS spectra will be interpreted with Mascot algorithms using target-decoy database strategies. Peptide/proteins will be quantified using label-free methods. 
2- Identification of potential biomarkers: 
a) The classification performance of distinctive peptides/proteins (potential biomarkers) in each group will be carried out using support vector machine (SVM) algorithms. The diagnostic performance of potential biomarkers will be based on sensitivity, specificity, positive and negative-predictive values and receiver-operator curves (ROC) for individual and combinations of biomarkers. 3- Data validation:
a) Biochemical validation of biomarkers will be carried out by repeating MS post-immuno-depletion of identified peptides (subject to antibody availability) and b) clinical validation will be carried out in an independent set of severe malaria cases and controls. This study will lay the foundations for the prospective validation of these biomarkers in a larger clinical study. 
4- Data integration: Supervised and unsupervised machine-learning algorithms will be used for feature extraction at three levels of information (proteomic, clinical and genome-wide data). These features will be used to create predictive models for pathobiological classification. These data will be used to generate theoretical network models. The topology of these networks will be used to identify critical pathophysiological steps leading to different pathophenotypes.</gtr:technicalSummary><gtr:fund><gtr:end>2012-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>921960</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECM</gtr:description><gtr:id>C6FA889D-43AF-46D1-B09B-89E2528C10D4</gtr:id><gtr:impact>manuscript (in preparation)</gtr:impact><gtr:outcomeId>bvpF615JVys-1</gtr:outcomeId><gtr:partnerContribution>Experimental model
Sample processing
Intellectual input</gtr:partnerContribution><gtr:piContribution>Proteomic characterisation of Experimental Cerebral malaria in phenotypically resistant mice in collaboration with Dr. Oliver Bilker</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Haemolysis</gtr:description><gtr:id>8CCE7C01-471D-483D-816D-CF32CA634967</gtr:id><gtr:impact>2 manuscripts (one accepted, one submitted)</gtr:impact><gtr:outcomeId>AjiW6kod7hu-1</gtr:outcomeId><gtr:partnerContribution>Materials and exchange of scientific data.</gtr:partnerContribution><gtr:piContribution>Collaborative research to identify markers of Haemolysis associated with Severe malaria with Dr. Hans Ackermann</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Computational Biology Research Group (CBRG)</gtr:department><gtr:description>SMALNET</gtr:description><gtr:id>8AB451D1-3FF8-4616-A78B-75F4DA0799D9</gtr:id><gtr:impact>A manuscript (submitted)</gtr:impact><gtr:outcomeId>iEacVvMEC7P-1</gtr:outcomeId><gtr:partnerContribution>We are currently seeking independent financial support for this consortium.</gtr:partnerContribution><gtr:piContribution>We have developed a strong collaboration with the Centre of Mathematical Biology (University of Oxford), the Central Proteomic Facility (Oxford) and 5 different African sites (Gambia, Gabon, Kenya, Malawi and Ghana).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>Gambia, Republic of the</gtr:country><gtr:department>MRC Unit, The Gambia</gtr:department><gtr:description>MRC Gambia</gtr:description><gtr:id>5F00B26B-953C-49AA-BC42-7D3C058CC280</gtr:id><gtr:impact>Manuscripts ( 2 submitted)</gtr:impact><gtr:outcomeId>sVbkYdXz1tF-1</gtr:outcomeId><gtr:partnerContribution>Patient recruitment and clinical samples</gtr:partnerContribution><gtr:piContribution>Identification of Biomarkers associated with severe Pneumonia and Malaria (Dr. Steve Howie, Prof. D'Alessandro, Dr. Davis Nwakanma)</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wellcome Centre for Clinical Tropical Medicine</gtr:department><gtr:description>Kilifi</gtr:description><gtr:id>9F98A172-6D57-4FF5-820B-7BEB8D3CAA18</gtr:id><gtr:impact>A manuscript (in preparation)</gtr:impact><gtr:outcomeId>efDiVwtwkMr-1</gtr:outcomeId><gtr:partnerContribution>Contributed clinical samples for validation.</gtr:partnerContribution><gtr:piContribution>We have developed a collaboration for cross-validation of biomarkers.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Keynot speaker EVIMALAR meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>73DC46C6-AD7E-4D59-939A-EF5AAE3D1758</gtr:id><gtr:impact>EVIMALAR is a european network of execellence. I have been recently made an affiliaqte member (open competition) and was invited a Keynote speaker in a recent cluster meeting.

A number of collaborations are likely to result from this presentation.</gtr:impact><gtr:outcomeId>S8evD3SnngW</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit (GCSE)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E45874C4-8348-4357-9067-7656BF6696DD</gtr:id><gtr:impact>Student Invitation to spend one week in our lab.

Presentation of the student in our lab and later in GCSE Science.</gtr:impact><gtr:outcomeId>DVb4PaajSfN</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ISIS press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>53AAF0B9-C65D-490D-86AB-3D9E5A18C266</gtr:id><gtr:impact>A press release by ISIS LTD (tecnhnology transfer company associated with Oxford Universtiy).

Interest expressed by two major diagnostic companies: Becton Dickinson (NC, US), Thermo</gtr:impact><gtr:outcomeId>dVLiDDah46S</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.isis-innovation.com/news/news/OxfordTeamFindMalariaMarkersforaQuickAccurateDiagnosis.html</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>141EC0D1-C4D8-42BF-872B-30A4AEC63668</gtr:id><gtr:impact>THe 2008 publication in PNAS was covered in the MRC network publication, the mRC website and by the weekend Science supplment of The Guardian (17/2/2008)

THis study has prompted a renewed interest in the potential use of Epo in cerebral malaria and a number of groups are considering the design of randomised controlled-trials to assess the efficacy of this molecule to prevent the development of neurological sequelae in cerebral malaria.</gtr:impact><gtr:outcomeId>DA13FFF08C7</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NDM Videopodcast [people behind the science]</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>169C1B88-8FEF-423C-922B-45C9EF0508F6</gtr:id><gtr:impact>The Nuffield Department of Medicine (University of Oxford) invited principal investigators to discuss their research projects in a videopodcast interview (ca. 10 in). The information is made available through iTunesU and the NDM webpage (http://www.ndm.ox.ac.uk/podcast-people-behind-the-science).

112 views</gtr:impact><gtr:outcomeId>tP1gXKYTQgb</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.youtube.com/watch?v=dXXLrYDuH3o</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release Oxford Mail Interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>93252A8C-8937-4C75-8919-3C2C1C11613C</gtr:id><gtr:impact>Brief interview with Oxford Mail regarding a newly discovered biomarker

Secondary Schools in Oxford asked for Seminar presenation in 2014</gtr:impact><gtr:outcomeId>pjkvoKpj3CS</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.oxfordmail.co.uk/news/10450300.Researchers_unlock____marker____for_malaria/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A panel of biomarker to indentify children with severe infection to improve paediatric patient referral</gtr:description><gtr:grantRef>G0701885</gtr:grantRef><gtr:id>5F459B27-A479-4DEC-9783-D653715531F3</gtr:id><gtr:impact>Currently exploring commercial interest with diagnostic companies (thorugh ISIS ltd)</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>dFGkAaQamUg</gtr:outcomeId><gtr:patentId>WO 2014041356 A2</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Biomarker</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A biomarker to identify acute malaria cases (with emphasis on development for blood screeing in transfusion services)</gtr:description><gtr:grantRef>G0701885</gtr:grantRef><gtr:id>F704CAE4-A35D-4440-9ED9-A6F78523426D</gtr:id><gtr:impact>ISIS is dicussing licencencing options with Becton_Dickinson. INternational pahse to start now.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>kSJQrNEQhEi</gtr:outcomeId><gtr:patentId>WO 2014006408 A1</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Biomarker (P. falciparum)</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E208D45E-078E-44A7-9562-24CFB06F733E</gtr:id><gtr:title>Proteomic identification of host and parasite biomarkers in saliva from patients with uncomplicated Plasmodium falciparum malaria.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e94754791b4be0de589dc01808c98d92"><gtr:id>e94754791b4be0de589dc01808c98d92</gtr:id><gtr:otherNames>Huang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>pm_13395_25_22640863</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87102A4A-0451-4055-849B-BEA15A7F6892</gtr:id><gtr:title>A better biomarker for cerebral malaria: in the eye of the beheld?*.</gtr:title><gtr:parentPublicationTitle>Critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ef6ee943732e11c819bdb57ea6b0667"><gtr:id>4ef6ee943732e11c819bdb57ea6b0667</gtr:id><gtr:otherNames>Ackerman HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0090-3493</gtr:issn><gtr:outcomeId>pm_13395_25_22343865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F60BEBD8-F8E1-4D39-926C-75FCBAB6F5D9</gtr:id><gtr:title>PfHPRT: a new biomarker candidate of acute Plasmodium falciparum infection.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75390f01ebbf73a71289fecc8de038c3"><gtr:id>75390f01ebbf73a71289fecc8de038c3</gtr:id><gtr:otherNames>Th?z?nas ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn><gtr:outcomeId>pm_13395_25_23339668</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F46FAE68-DAEF-4E05-AF9B-FE6719358CE3</gtr:id><gtr:title>Clinical features of severe malaria associated with death: a 13-year observational study in the Gambia.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f21f1d98cd7f57fabc7b6af7b890e47"><gtr:id>5f21f1d98cd7f57fabc7b6af7b890e47</gtr:id><gtr:otherNames>Jallow M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13395_25_23029157</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61D17C55-AFFB-4728-886E-ACF544576B09</gtr:id><gtr:title>Can erythropoietin be used to prevent brain damage in cerebral malaria?</gtr:title><gtr:parentPublicationTitle>Trends in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b50d5a90653420ac6a2147b60ddbafdb"><gtr:id>b50d5a90653420ac6a2147b60ddbafdb</gtr:id><gtr:otherNames>Casals-Pascual C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-4922</gtr:issn><gtr:outcomeId>816BFF6B4A5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B075814-83D6-4584-87A8-09A7E5EE55CA</gtr:id><gtr:title>Proteomic profiling of the brain of mice with experimental cerebral malaria.</gtr:title><gtr:parentPublicationTitle>Journal of proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0baf029ad3b040caaac9572457f28c17"><gtr:id>0baf029ad3b040caaac9572457f28c17</gtr:id><gtr:otherNames>Moussa E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1874-3919</gtr:issn><gtr:outcomeId>5aa68a74d32b14.23791920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77FE1839-3062-4F5E-A381-E636C54D5A00</gtr:id><gtr:title>Hepcidin demonstrates a biphasic association with anemia in acute Plasmodium falciparum malaria.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b50d5a90653420ac6a2147b60ddbafdb"><gtr:id>b50d5a90653420ac6a2147b60ddbafdb</gtr:id><gtr:otherNames>Casals-Pascual C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>pm_13395_25_22689680</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDDAD659-F4FD-4555-B5EC-D17E41FEB95D</gtr:id><gtr:title>Interleukin-10 regulates hepcidin in Plasmodium falciparum malaria.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e94754791b4be0de589dc01808c98d92"><gtr:id>e94754791b4be0de589dc01808c98d92</gtr:id><gtr:otherNames>Huang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54623d5e290a98.49875716</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8ECB8F9F-5807-4A2F-BD69-98ADCFF7D07F</gtr:id><gtr:title>Discovery and validation of biomarkers to guide clinical management of pneumonia in African children.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e94754791b4be0de589dc01808c98d92"><gtr:id>e94754791b4be0de589dc01808c98d92</gtr:id><gtr:otherNames>Huang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>54623d5e023052.96459045</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A616B02-85B1-4FB2-AC82-A620799E9D99</gtr:id><gtr:title>Continued decline of malaria in The Gambia with implications for elimination.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f0c436672f5d43f5d7799e36196b76b"><gtr:id>8f0c436672f5d43f5d7799e36196b76b</gtr:id><gtr:otherNames>Ceesay SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>Mo8Vu862X6P</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701885</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>